Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients
|ClinicalTrials.gov Identifier: NCT01828619|
Recruitment Status : Unknown
Verified April 2013 by FENGRONG WANG, Peking University People's Hospital.
Recruitment status was: Enrolling by invitation
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
|Condition or disease||Intervention/treatment|
|Leukemia Myelodysplastic Syndrome||Procedure: modified BuFlu conditioning|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||December 2015|
modified BuFlu, HSCT, elder/intolerable
The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
Procedure: modified BuFlu conditioning
The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
- stem cell engraftment [ Time Frame: 30day post transplantation ]
- toxicity and treatment related mortality [ Time Frame: 100day and 1 year post transplantation ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828619
|Peking University People's Hospital|
|Beijing, China, 100044|
|Principal Investigator:||XiaoJun Huang, MD||Peking University People's Hospital, Department of Hematology|